JUBILANT DRAXIMAGE INC

For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the US FDA.

The acquisition will be done through a arm Jubilant DraxImage Inc and funded via internal accruals, sources told ET Now.

Jubilant Pharma, through one of its units JDI, has received approval from TGA, Australia, for Lyophilized kit for preparation of Technetium...